Related Experiment Video
Updated: Jul 6, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
David A Reardon1, Patrick Y Wen, Annick Desjardins
1Duke University Medical Center, Neuro-Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA. reard003@mc.duke.edu
Background:
Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors.
Objective:
To summarize the clinical experience of VEGF-directed treatment for malignant glioma.
Methods:
We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients.
Results/Conclusions:
Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
